Wide Ranks

BDSX

Biodesix, Inc.

1.43

Top Statistics
Market Cap 207 M Forward PE -6.48 Revenue Growth 34.50 %
Current Ratio 3.40 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -66.84 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.16 Enterprise / Revenue 3.64 Price To Sales Trailing12 Months 3.16
Profitability
Profit Margins -66.84 % Operating Margins -47.33 %
Balance Sheet
Total Cash 31 M Total Cash Per Share 0.2160 Total Debt 62 M
Total Debt To Equity 226.08 Current Ratio 3.40 Book Value Per Share 0.1920
All Measures
Short Ratio 113.00 % Message Board Id finmb_36508169 Fax 866 432 3338
Shares Short Prior Month 415133 Return On Equity -3.32 City Louisville
Uuid df9e8662-6fbd-3fb4-9173-ec4974f5206d Previous Close 1.44 First Trade Date Epoch Utc 1 B
Book Value 0.1920 Beta 1.21 Total Debt 62 M
Volume 289796 Price To Book 7.42 Fifty Two Week Low 1.11
Total Cash Per Share 0.2160 Total Revenue 65 M Shares Short Previous Month Date 1 B
Target Median Price 3.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -47.33 % Target Mean Price 3.10 Net Income To Common -43819000
Short Percent Of Float 0.0042 Implied Shares Outstanding 145 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 31 M Next Fiscal Year End 1 B Revenue Per Share 0.5660
Held Percent Insiders 0.4862 Ebitda Margins -44.63 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.44
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.54
Open 1.45 Free Cashflow -43438876 State CO
Dividend Yield 0.00 % Return On Assets -0.2279 Time Zone Short Name EST
Trailing Eps -0.3700 Day Low 1.42 Address1 919 West Dillon Road
Shares Outstanding 145 M Price Hint 4 Target High Price 3.50
Website https://www.biodesix.com 52 Week Change -0.0436 Average Volume 395067
Forward Eps -0.2200 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 304.30 % Is_sp_500 False Regular Market Day High 1.50
Profit Margins -66.84 % Debt To Equity 226.08 Fifty Two Week High 2.21
Day High 1.50 Shares Short 388861 Regular Market Open 1.45
Industry Key diagnostics-research Earnings Growth 0.00 % Enterprise To Revenue 3.64
Revenue Growth 34.50 % Shares Percent Shares Out 0.0027 Operating Cashflow -56836000
Currency USD Time Zone Full Name America/New_York Market Cap 207 M
Is_nasdaq_100 False Zip 80027 Quote Type EQUITY
Industry Diagnostics & Research Long Name Biodesix, Inc. Regular Market Day Low 1.42
Held Percent Institutions 0.4283 Current Price 1.43 Enterprise To Ebitda -8.16
Financial Currency USD Current Ratio 3.40 Gross Margins 77.72 %
Industry Disp Diagnostics & Research Number Of Analyst Opinions 5 Country United States
Float Shares 68 M Two Hundred Day Average 1.55 Enterprise Value 238 M
Price To Sales Trailing12 Months 3.16 Forward PE -6.48 Regular Market Volume 289796
Ebitda -29259000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.

The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions.

In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.

Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.

The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006.

Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.